UNSPSC 51284300: Amphenicols

This classification denotes phenylalanine-based, phenylpropanoids and antibacterials thar inhibit bacterial protein synthesis, and which are therefore called AMPHENICOLS.

UNSPSC 51284300 Amphenicols is a Class code under which state and local governments procure pharmaceuticals, medical supplies, and related health-care products—though recent opportunities show the code capturing a broader range of health-system acquisitions than amphenicol antibiotics alone. Solicitations under this code span naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and OTC products through cooperative purchasing alliances, medical and first aid supplies for fire-rescue operations, and direct-to-manufacturer prescription fulfillment programs. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and multi-state cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, serving both Minnesota and Oregon). The code attracts both traditional competitive bidding and collaborative procurement mechanisms, with set-asides present in some opportunities—notably, Tampa's medical and first aid supplies solicitation is sheltered for certified Small Local Business Enterprises with a 5 percent bid discount capped at $10,000.

Recent activity concentrates in Florida, Minnesota, Oregon, and Texas. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries; the City of Tampa's ITB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 for the Tampa Fire Department Rescue Division; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across member states with product availability required by May 15, 2026 and effective July 1, 2026. The Texas HHS RFI HHS0017013 (posted April 3, 2026) explores direct-to-manufacturer prescription programs, signaling state interest in alternative pharmacy benefit structures beyond traditional PBM and GPO channels.